GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Total Debt per Share

Rhinomed (ASX:RNO) Total Debt per Share : A$0.02 (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Total Debt per Share?

A$0.02 (As of Jun. 2023)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Rhinomed's Total Debt Per Share for the quarter that ended in Jun. 2023 was A$0.02.

Rhinomed Total Debt per Share Historical Data

The historical data trend for Rhinomed's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Total Debt per Share Chart

Rhinomed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.02

Rhinomed Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.02 0.02

Rhinomed Total Debt per Share Calculation

Rhinomed's Total Debt Per Share for the fiscal year that ended in Jun. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.02+5.96)/285.72
=0.02

Rhinomed's Total Debt Per Share for the quarter that ended in Jun. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.02+5.96)/285.72
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhinomed Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Rhinomed's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhinomed (ASX:RNO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Total Debt per Share
Comparable Companies
ASX:VTI ASX:IRX ASX:CBL ASX:HMD ASX:UCM ASX:OSL ASX:AT1 ASX:AMT ASX:LBT ASX:CSX ABT SYK MDT BSX EW SZSE:300760 DXCM ZBH ALGN STE
Traded in Other Exchanges
RHNMF:USA
Address
132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121
Website
https://www.rhinomed.global
Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines